| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
BeiGene Ltd (NASDAQ: BGNE)
BGNE Technical Analysis
1.5
| As on 9th Jun 2023 BGNE STOCK Price closed @ 216.04 and we RECOMMEND Buy for LONG-TERM with Stoploss of 182.30 & Sell for SHORT-TERM with Stoploss of 230.23 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BGNESTOCK Price
| Open | 216.93 | Change | Price | % |
| High | 219.29 | 1 Day | -1.02 | -0.47 |
| Low | 215.03 | 1 Week | -4.89 | -2.21 |
| Close | 216.04 | 1 Month | -39.45 | -15.44 |
| Volume | 157100 | 1 Year | -59.22 | -21.51 |
| 52 Week High 275.26 | 52 Week Low 121.11 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| BGNE Daily Charts |
BGNE Intraday Charts |
Whats New @ Bazaartrend |
BGNE Free Analysis |
|
|
BGNE Important Levels Intraday
| RESISTANCE | 224.25 |
| RESISTANCE | 221.62 |
| RESISTANCE | 219.99 |
| RESISTANCE | 218.36 |
| SUPPORT | 213.72 |
| SUPPORT | 212.09 |
| SUPPORT | 210.46 |
| SUPPORT | 207.83 |
BGNE Forecast May 2024
| 4th UP Forecast | 337.07 |
| 3rd UP Forecast | 298.26 |
| 2nd UP Forecast | 274.26 |
| 1st UP Forecast | 250.27 |
| 1st DOWN Forecast | 181.81 |
| 2nd DOWN Forecast | 157.82 |
| 3rd DOWN Forecast | 133.82 |
| 4th DOWN Forecast | 95.01 |
BGNE Weekly Forecast
| 4th UP Forecast | 283.29 |
| 3rd UP Forecast | 261.72 |
| 2nd UP Forecast | 248.39 |
| 1st UP Forecast | 235.06 |
| 1st DOWN Forecast | 197.02 |
| 2nd DOWN Forecast | 183.69 |
| 3rd DOWN Forecast | 170.36 |
| 4th DOWN Forecast | 148.79 |
BGNE Forecast2024
| 4th UP Forecast | 529.06 |
| 3rd UP Forecast | 428.67 |
| 2nd UP Forecast | 366.62 |
| 1st UP Forecast | 304.57 |
| 1st DOWN Forecast | 127.51 |
| 2nd DOWN Forecast | 65.46 |
| 3rd DOWN Forecast | 3.41 |
| 4th DOWN Forecast | -96.98 |
BeiGene Ltd ( NASDAQ USA Symbol : BGNE )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BGNE Business Profile
BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China and the United States. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene, Ltd. has a strategic collaboration with Shoreline Biosciences, Inc. to develop and commercialize a portfolio of NK-based cell therapeutics. The company was incorporated in 2010 and is based in Grand Cayman, Cayman Islands. Address: 94 Solaris Avenue, Grand Cayman, Cayman Islands, KY1-1108
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service